Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung

被引：15
|
作者：
Reichegger, Hermann [1 ]
Jochum, Wolfram [2 ]
Forbs, Diana [2 ]
Hader, Claudia [3 ]
Fruh, Martin [1 ]
机构：
[1] Kantonsspital St Gallen, Dept Med Oncol & Hematol, Rorschacherstr 95, CH-9007 St Gallen, Switzerland
[2] Kantonsspital St Gallen, Inst Pathol, St Gallen, Switzerland
[3] Kantonsspital St Gallen, Dept Radiol & Nucl Med, St Gallen, Switzerland
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷 / 7-8期
关键词：
AZD9291; Osimertinib; Intracranial; Lung cancer; Response; EGFR mutation; T790M; EGFR-TKI; ACQUIRED-RESISTANCE; CANCER; AZD9291; METASTASES; INHIBITORS; MUTATION;
D O I：
10.1159/000446759
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Osimertinib (AZD9291, Tagrisso) is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Case Report: Our report demonstrates that osimertinib is able to inhibit the growth of a radiotherapy- and surgery-refractory EGFR T790M-positive brain metastasis in a patient with lung adenocarcinoma. Conclusion: These data show that re-biopsy in EGFR-mutated non-small cell lung cancer patients with acquired TKI resistance should be performed. (C) 2016 S. Karger GmbH, Freiburg
引用
收藏
页码：461 / 463
页数：3
相关论文
共 50 条
  • [21] Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment
    Nakao, Akira
    Hiranuma, Osamu
    Uchino, Junji
    Sakaguchi, Chikara
    Araya, Tomoyuki
    Hiraoka, Noriya
    Ishizuka, Tamotsu
    Takeda, Takayuki
    Kawasaki, Masayuki
    Goto, Yasuhiro
    Imai, Hisao
    Hattori, Noboru
    Nakatomi, Keita
    Uramoto, Hidetaka
    Uryu, Kiyoaki
    Fukuda, Minoru
    Uchida, Yasuki
    Yokoyama, Toshihide
    Akai, Masaya
    Mio, Tadashi
    Nagashima, Seiji
    Chihara, Yusuke
    Tamiya, Nobuyo
    Kaneko, Yoshiko
    Mouri, Takako
    Yamada, Tadaaki
    Yoshimura, Kenichi
    Fujita, Masaki
    Takayama, Koichi
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06) : 1 - 12
  • [22] Osimertinib: a breakthrough for the treatment of epidermal growth factor receptor mutant lung adenocarcinoma
    Karachaliou, Niki
    Barron Barron, Feliciano
    Viteri, Santiago
    Angel Molina, Miguel
    Rosell, Rafael
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S117 - S121
  • [23] Osimertinib for EGFR-Positive NSCLC Patients with Leptomeningeal Metastases Harboring T790M-Positive or T790M-Negative Mutations
    Xu, H.
    Zhang, Y.
    Kong, J.
    Yang, G.
    Yang, L.
    Liu, S.
    Wang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S612 - S613
  • [24] Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation In vivo
    Ichihara, Eiki
    Ohashi, Kadoaki
    Takigawa, Nagio
    Osawa, Masahiro
    Ogino, Atsuko
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    CANCER RESEARCH, 2009, 69 (12) : 5091 - 5098
  • [25] An Analysis of 5-Level Version of EQ-5D Adjusting for Treatment Switching: The Case of Patients With Epidermal Growth Factor Receptor T790M-Positive Nonsmall Cell Lung Cancer Treated With Osimertinib
    Singh, Jeshika
    Bourke, Siobhan
    Dyer, Matthew
    Devlin, Nancy
    Longworth, Louise
    VALUE IN HEALTH, 2022, 25 (07) : 1205 - 1211
  • [26] Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib
    Wang, Hanping
    Pan, Ruili
    Zhang, Xiaotong
    Si, Xiaoyan
    Wang, Mengzhao
    Zhang, Li
    THORACIC CANCER, 2020, 11 (03) : 594 - 602
  • [27] Comparison of the Treatment Efficacy of Osimertinib in Young and Elderly Patients with T790M-Positive NSCLC
    Kato, Y.
    Hosomi, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S887 - S887
  • [28] Reuse of osimertinib after small cell lung cancer transformation in lung adenocarcinoma with de-novo epidermal growth factor receptor T790M mutation: case report
    Wang, Xiuwen
    Liang, Jizhen
    Li, Li
    Pan, Zhaojun
    Wang, Lin
    ANTI-CANCER DRUGS, 2023, 34 (02) : 306 - 310
  • [29] T790M Mutation and Clinical Outcomes with Osimertinib in Patients with Epidermal Growth Factor Receptor-mutant Nonsmall Cell Lung Cancer
    Jaiswal, Ravi
    Pinninti, Rakesh
    Mohan, M. V. T. Krishna
    Santa, A.
    Boyella, Pavan Kumar
    Nambaru, Lavanya
    Murthy, Sudha S.
    Chowdary, K. Veeriah
    Rajappa, Senthil
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (01) : 73 - 78
  • [30] Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment
    Su, Po-Lan
    Tsai, Jeng-Shiuan
    Yang, Szu-Chun
    Wu, Yi-Lin
    Tseng, Yau-Lin
    Chang, Chao-Chun
    Yen, Yi-Ting
    Lin, Chia-Ying
    Lin, Chien-Chung
    Wang, Chin-Chou
    Lin, Meng-Chih
    Su, Wu-Chou
    LUNG CANCER, 2021, 158 : 137 - 145
12345